Source: Annual Congress 2006 - Diagnosis and treatment in community-acquired pneumonia
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
H. L. Baradzina, N. V. Manovitskaya (Minsk, Belarus). Efficiency of two-colored magnetic-laser therapy in pneumonia. Eur Respir J 2006; 28: Suppl. 50, 2231

Member's Comments

No comment yet.

Related content which might interest you: Two-coloured magnetic-laser therapy in sarcoidosis Source: Eur Respir J 2005; 26: Suppl. 49, 81s Year: 2005 Efficacy of α-tocoferol in the treatment of patients with pneumonia Source: Annual Congress 2008 - Animal models of pulmonary fibrosis: mechanisms and therapies Year: 2008 Safety and efficacy of CURB65 guided antibiotic therapy in community-acquired pneumonia Source: Annual Congress 2010 - The prognosis of community-acquired pneumonia: old and new markers of severity Year: 2010 Efficacy and safety of stepwise therapy in patients with community-acquired pneumonia Source: Eur Respir J 2006; 28: Suppl. 50, 377s Year: 2006 Empirical treatment of community-acquired pneumonia after outpatient beta-lactam therapy Source: International Congress 2016 – Community-acquired pneumonia: from prevention to treatment Year: 2016 Strategies for de-escalation of therapy in patients with hospital-acquired pneumonia Source: Eur Respir J 2007; 30: Suppl. 51, 408s Year: 2007 Etiology and etiotropic therapy of angiogenic sepsis Source: Eur Respir J 2003; 22: Suppl. 45, 452s Year: 2003 Modification of empirical antibiotic therapy in community acquired pneumonia Source: International Congress 2014 – Different interesting issues in respiratory infections: 2 Year: 2014 Corticosteroids as adjunctive therapy in tuberculosis pneumonia with ART Source: Breathe 2008; 5: 274 Year: 2009 Dynamic of adherence to guidelines for antibiotic therapy of community-aquired pneumonia (CAP) Source: Annual Congress 2013 –Antibiotics, resistance and vaccines Year: 2013 Evaluation of severity score-guided approaches to macrolide use in community-acquired pneumonia Source: Eur Respir J, 50 (3) 1602306; 10.1183/13993003.02306-2016 Year: 2017 Multicolored magnetic-laser therapy in asthma patients Source: Eur Respir J 2004; 24: Suppl. 48, 510s Year: 2004 Efficacy of corticosteroids in hospital treated community-acquired pneumonia Source: Annual Congress 2012 - Clinical management of lung diseases: from bronchi to pleura Year: 2012 Comparison of ampicillin-sulbactam/macrolide dual therapy versus fluoroquinolone monotherapy in hospitalized patients with community-acquired pneumonia Source: International Congress 2015 – Clinical issues in CAP: microbiological and radiological determinants Year: 2015 Comparative evaluation of timing of antibiotic intravenous-to-oral switch in pneumonia Source: International Congress 2014 – Antibiotics, antifungals and other therapeutic options Year: 2014 Inhaled antibiotics in ventilator-associated pneumonia: treatment or prophylaxis? Source: International Congress 2016 – PG13 Inhaled antibiotics in respiratory infections Year: 2016 Adjunctive systemic corticosteroid treatment in hospitalized patients with community-acquired pneumonia Source: Annual Congress 2012 - Anti-infective treatment and resistance in respiratory infections Year: 2012 Late Breaking Abstract - Effect of adjunctive tobramycin inhalation therapy in the treatment of ventilator-associated pneumonia: findings from the randomized VAPORISE trial Source: International Congress 2019 – Recent developments in intensive care unit medicine Year: 2019 Frequency of side effects in antibiotic treatment for pneumonia Source: International Congress 2019 – Clinical challenges in respiratory infection Year: 2019 Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia Source: Eur Respir J 2010; 36: 128-134 Year: 2010